S ensitive assays for measurement of cardiac troponin T (cTnT) and troponin I (cTnI) have recently been introduced in clinical practice and are essential for the diagnosis of acute myocardial infarction (MI).
HF (CORONA), performed in older patients with systolic HF of ischemic origin. In CORONA, rosuvastatin did not reduce the primary composite outcome (death from CV causes, nonfatal MI, and nonfatal stroke) or all-cause mortality. The predictive value of elevated baseline hs-cTnT and the prognostic value of changes in hs-cTnT levels from baseline to 3-month follow-up were evaluated, as well as possible interactions with statin therapy. We hypothesized that hs-cTnT would provide additional prognostic and discriminating information beyond that of established HF risk factors in this patient cohort.
Methods Patients
The design and principal findings of CORONA have been reported in detail. 15 Briefly, patients aged ≥60 years with chronic HF attributed to ischemic heart disease, defined as (1) medical history or ECG signs of old MI or (2) other data indication ischemic cause of HF (ie, wall motion disturbances on echocardiography, left bundle branch block, or history of other occlusive atherosclerotic disease [ie, earlier stroke, intermittent claudication, percutaneous coronary intervention]), who were in New York Heart Association (NYHA) class II-IV, with a left ventricular ejection fraction ≤40% (≤35% if NYHA II), were eligible, provided the investigator thought they did not need treatment with a cholesterol-lowering drug. The main criteria for exclusion were a recent CV event, current or planned procedures or operations, acute or chronic liver disease, serum creatinine ≥2.5 mg/dL, contraindications to statin therapy, or unexplained increase in creatine kinase. All patients provided written informed consent. Patients were randomly assigned to rosuvastatin 10 mg/d or matching placebo, once daily.
Study Procedures
The trial complied with the Declaration of Helsinki and was approved by the Ethics Committees of the participating hospitals. All patients provided written informed consent. Patients were randomly assigned to rosuvastatin 10 mg/d or matching placebo, once daily. The present study was a predefined substudy of the main CORONA trial, which included 1480 consecutive patients (hs-cTnT was measured in 1245 patients with samples available at both baseline and 3 months). There were only minor differences in the baseline characteristics between this substudy and the main CORONA study (Table I in the Data  Supplement) .
Study Outcomes and Definitions
The primary predefined outcome was the composite of death from CV causes, nonfatal MI, and nonfatal stroke, analyzed as time to the first event. Of secondary outcomes, the following were used in this substudy: (1) all-cause mortality, (2) CV mortality, and (3) composite of CV mortality and hospitalizations from worsening of HF (WHF). The definition and adjudication of all outcomes, as well as data on high-sensitivity C-reactive protein (hs-CRP) and amino-terminal probrain natriuretic peptide (NT-proBNP), have been described in detail.
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Blood Sampling and Biochemical Analyses
TnT was measured in blood samples taken after an overnight fast with a high-sensitivity assay (Roche Diagnostics, Basel, Switzerland) on a Roche Modular E170 platform using the Elecsys reagents (Roche Diagnostics). This hs-cTnT assay has a detection limit of 3 ng/L, a 99th percentile cutoff of 14 ng/L, and a coefficient of variation of <10% at 13 ng/L. Hs-cTnT levels below detection limit were set to 3 ng/L in the statistical analyses. All other blood samples were nonfasting and analyzed on fresh samples at a central laboratory (Medical Research Laboratories, Zaventem, Belgium). NT-proBNP was analyzed using commercially available assay (Roche Diagnostics, Basel, Switzerland). An immunonephelometric high-sensitivity method was used to measure CRP (Dade Behring, Atterbury, UK; sensitivity, 0.04 mg/L).
Statistical Analysis
For all baseline variables, differences between patients with hs-cTnT levels > or ≤14 ng/L (99th percentile) were tested with the Student t test for normally distributed variables, Fisher exact test for categorical data, and Wilcoxon rank-sum test for non-normally distributed variables. The natural log was used for logarithmic transformations. All variables with a significant univariate association with hs-cTnT levels were included in a stepwise logistic regression to explore their combined explanatory power of hs-cTnT levels. All survival analyses were conducted using the Cox proportional hazard regression model where hs-cTnT was included as a dichotomized variable (±14 ng/L) in a multivariable analysis that included left ventricular ejection fraction, NYHA class, age, body mass index, diabetes mellitus, sex, intermittent claudication, heart rate, estimated glomerular filtration rate (eGFR), apolipoprotein B/apolipoprotein A-1 ratio, log-transformed (natural log) plasma concentrations of NT-proBNP, and hs-CRP. The Harrell C-statistic was calculated for all end points using the multivariable model with and without hs-cTnT, and the difference between the C-statistics was estimated. To correct for overoptimism associated with validating a model in the same material from which it is developed, we implemented a jack-knife cross-validation approach, where predictions for each observation were obtained from models developed on the remaining observations. These cross-validated probabilities were used to calculate jack-knife C-statistics. Recently, calculation of net reclassification improvement (NRI) has been suggested for the evaluation of the prognostic usefulness of a biomarker. 19 In particular, when no established risk categories exist, the use of a category-free NRI has been advocated. 20 We therefore calculated the category-free NRI after adding hs-cTnT to the multivariable model. Confidence intervals and P values for NRI were determined by bootstrapping with 2000 repetitions. For the analysis of changes in hs-cTnT concentrations from baseline to 3-month follow-up, a 15% relative change was used as cutoff, which is consistent with other studies.
14 A 2-sided P <0.05 was considered to be significant, except for interaction terms for which values of P <0.10 were accepted. All statistical analyses were performed using STATA version 11 for Windows (StataCorp, College Station, TX). The authors had full access to and take responsibility for the integrity of the data. All authors have read and agreed to the article as written.
Results
Baseline Characteristics
In our study population, 1078 patients (86.6%) had hs-cTnT levels above the detection limit (3 ng/L) of the assay. The baseline characteristics of patients dichotomized according to the 99th percentile to hs-cTnT (14 ng/L) are shown in Table 1 . Patients with hs-cTnT levels >14 ng/L were older, more frequently men, had lower left ventricular ejection fraction, lower body mass index, and higher heart rate than those with hs-cTnT levels ≤14 ng/L. In addition, patients with hs-cTnT levels >14 ng/L had a higher prevalence of atrial fibrillation, other atherosclerotic diseases, previous percutaneous coronary intervention, diabetes mellitus, hypertension, and chronic obstructive pulmonary disease. Patients with hs-cTnT above the 99th percentile were more frequently treated with aldosterone antagonists, diuretics, and digitalis glycosides. On the contrary, a history of angina pectoris and the use of β-blockers were less prevalent in patients with hs-cTnT >14 ng/L than in those with hs-cTnT levels ≤14 ng/L. Patients with hs-cTnT levels >14 ng/L had lower total and low-density lipoprotein cholesterol levels and a lower average eGFR but had higher levels of NT-proBNP and hs-CRP. Demographic, clinical, and biochemical baseline characteristics stratified by serum high-sensitive troponin T (hs-cTnT) levels below or above the 99th percentile (14 ng/L). High-sensitivity C-reactive protein (hs-CRP), amino-terminal probrain natriuretic peptide (NT-proBNP), and hs-cTnT levels are displayed as median value (25th-75th percentiles). Other variables are shown as numbers (% of total) or mean (SD), where appropriate. ACE indicates angiotensin-converting enzyme; ApoA-1, apolipoprotein A-1; ApoB, apolipoprotein B; BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, highdensity lipoprotein; LDL, low-density lipoprotein; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and SBP, systolic blood pressure. Table 1 that were significantly associated with elevated hs-cTnT levels were included in a linear regression model, NT-proBNP levels, diabetes mellitus, history of coronary revascularization, age, use of digitoxin/ digoxin, diuretics and β-blockers, hs-CRP levels, systolic and diastolic blood pressures, heart rate, female sex, and eGFR remained independently associated with hs-cTnT levels, explaining 47.1% (R 2 ) of the variation (Table 2) . Of these variables, NT-proBNP was the strongest predictor of elevated hs-cTnT levels.
When all variables in
Effect of Rosuvastatin Treatment on hs-cTnT Levels and Clinical Outcomes
The difference in hs-cTnT concentrations at baseline and 3-month follow-up was not statistically different, neither among patients receiving placebo nor in the rosuvastatin group. Importantly, there was no statistically significant interaction between hs-cTnT levels and treatment with rosuvastatin.
Association Between High-Sensitivity cTnT Levels and Outcomes
During a median follow-up of 955 (25th-75th percentiles, 817-1003) days, 366 patients died. Restricted cubic spline analysis demonstrated linearity between risk for all-cause mortality and log-transformed hs-cTnT levels ( Figure 1 ). Kaplan-Meier plots for the primary end point, all-cause mortality, CV mortality, and the composite of CV mortality and hospitalization from WHF demonstrated a significantly higher frequency of events for patients with hs-cTnT levels >14 ng/L compared with those with hs-cTnT levels ≤14 ng/L (Figure 2 ). Hs-cTnT levels, both dichotomized according to the 99th percentile (Table 3 ) and as a continuous variable (Table 4) , were associated with the primary end point, as well as all-cause mortality, CV mortality, and the composite of CV mortality and hospitalization from WHF in a multivariable regression model adjusting for demographic and clinical variables, as well as NT-proBNP, hs-CRP, and eGFR. Similar associations were also found when the relationship between hs-cTnT and outcomes was assessed according to quartiles of hs-cTnT levels (Table II in the Data Supplement) . Importantly, hs-cTnT levels dichotomized according to the 99th percentile (14 ng/L) remained a significant predictor of outcome in an extended multivariable regression model, also including systolic and diastolic blood pressures, history of angina pectoris, history of atherosclerotic disease, history of previous revascularization, hypertension, atrial fibrillation, chronic obstructive pulmonary disease, total cholesterol, low-density lipoprotein levels, use of diuretics, use of aldosterone antagonists, use of β-blockers, and use of digitalis glycoside (Table 3) . Comparisons among hs-cTnT, hs-CRP, and NT-proBNP, as predictors of outcome in this study population, have also been performed (Table III in 
Value of hs-cTnT in Prognostic Discrimination
To assess the value of hs-cTnT in prognostic discrimination, NRI analyses were performed. Introduction of hs-cTnT levels to the multivariable model (including hs-CRP and NT-proBNP) significantly improved prognostic discrimination of the primary end point, as well as all-cause mortality, CV mortality, and the composite of CV mortality and hospitalization from WHF, as indicated by the NRI scores (Table 4) . However, improved discrimination as assessed by C-statistics was only seen for the primary end point and all-cause mortality.
Changes in hs-cTnT Levels Over Time and Relationship With Outcomes
Overall, 300 patients (29%) had a >15% increase in hs-cTnT between baseline and 3 months. Of these, 183 (61%) patients had a baseline hs-cTnT ≤14 ng/L and 117 (39%) had a baseline hs-cTnT >14 ng/L. Such an increase was associated with A linear regression model was performed to identify factors that are significantly associated with increasing log-transformed levels of serum high-sensitive troponin T (hs-cTnT). CABG indicates coronary artery bypass grafting; CI, confidence interval; Coef, regression coefficient with corresponding P value; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, amino-terminal probrain natriuretic peptide; PCI, percutaneous coronary intervention; and SBP, systolic blood pressure. a higher risk of the composite end point of CV mortality or hospitalization because of WHF but not with any of the other prespecified end points, including the primary end point (Figure 3) . The predictive value of absolute changes in hs-cTnT levels from baseline to 3 months was inferior to that of relative change (data not shown).
Discussion
Our data demonstrate that elevated hs-cTnT levels had a strong predictive and discriminating value for the primary end point, all-cause mortality, CV mortality, and the composite of CV mortality and hospitalizations because of WHF among older patients with chronic HF of ischemic origin. Although hscTnT levels in the CORONA population in relation to serum levels of gp130, a marker of activity in the interleukin-6 system, have already been reported, 21 the present post hoc analysis from CORONA includes more comprehensive data on the hs-cTnT levels in this patient population.
The predictive value of elevated hs-cTnT levels was explored both dichotomized according to the 99th percentile and as a continuous variable in the present study. The choice of 14 ng/L as a cutoff was motivated by its clinical importance because 14 ng/L is equal to the 99th percentile of hs-cTnT in a healthy population. 22 We wanted to test the prognostic importance of normal versus pathological levels of hs-cTnT in an HF population. Because the restricted cubic spline plot for hscTnT in relation to all-cause mortality showed a linear relationship, we also investigated the predictive value of hs-cTnT as a continuous variable.
The study includes several clinical end points. Importantly, the primary end point is equal to the predefined primary end point in the original CORONA study. 15 The rationale for combining CV Figure 1 . Restricted cubic spline analysis (fitted curve with 95% confidence interval) demonstrating linearity between risk for allcause mortality and log-transformed high-sensitive troponin T (hs-cTnT) levels.
Figure 2.
Kaplan-Meier curves demonstrating the cumulative incidence of the primary end point, all-cause mortality, cardiovascular (CV) mortality, and composite of CV mortality and hospitalization from worsening of heart failure (WHF) in all patients according to high-sensitive troponin T (hs-cTnT) levels > or ≤14 ng/L. mortality and hospitalizations is an attempt to combine mortality and morbidity to reflect the true burden of the HF syndrome. The effect of mortality is obvious, but the effect of hospitalizations might be underestimated in clinical trials. 23 Although several previous studies have identified elevated cTnT or cTnI as markers of adverse events in chronic HF even after adjustment for BNP or NT-proBNP, those studies differed significantly from ours, having included smaller The table shows log-transformed levels of serum high-sensitive troponin T (hs-cTnT) as a continuous variable as a predictor of outcome. All hazard ratios (HRs) are given as HR (95% confidence interval [CI]). ΔC index: difference in C index between adjusted models with and without inclusion of hs-cTnT with corresponding P value. Net reclassification improvement (NRI) calculated for fully adjusted models with and without inclusion of hs-cTnT with corresponding P value. The multivariable regression model includes the following risk factors: left ventricular ejection fraction, New York Heart Association class, age, body mass index, diabetes mellitus, sex, intermittent claudication, heart rate, apolipoprotein B/apolipoprotein A-1 ratio, amino-terminal probrain natriuretic peptide, high-sensitivity C-reactive protein, and estimated glomerular filtration rate. CV indicates cardiovascular; and WHF, worsening of heart failure. High-sensitive troponin T (hs-cTnT) as a predictor of outcome, included as a dichotomized variable (14 ng/L). All hazard ratios (HRs) are given as HR (95% confidence interval [CI]) with corresponding P value. The multivariable regression model includes the following risk factors: left ventricular ejection fraction, New York Heart Association class, age, body mass index, diabetes mellitus, sex, intermittent claudication, heart rate, apolipoprotein B/apolipoprotein A-1 ratio, amino-terminal probrain natriuretic peptide, high-sensitivity C-reactive protein, and estimated glomerular filtration rate. The extended multivariable regression model also includes the following risk factors: systolic blood pressure, diastolic blood pressure, history of angina pectoris, history of atherosclerotic disease, history of previous revascularization, hypertension, atrial fibrillation, chronic obstructive pulmonary disease, total cholesterol, low-density lipoprotein levels, use of diuretics, use of aldosterone antagonists, use of β-blockers, and use of digitalis glycoside. CV indicates cardiovascular; and WHF, worsening of heart failure.
numbers of patients, few elderly patients, or a small proportion of patients in NYHA functional class III or IV. 12, 24, 25 In particular, our data differ somewhat from those in a report from the Val-HeFT (Valsartan Reduces Morbidity in Chronic Heart Failure) and GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nellInsufficienza Cardiaca-Heart Failure) trials, which showed that changes in hs-cTnT concentrations over time predicted CV events among patients with HF but, however, added limited prognostic discrimination. 14 In this CORONA substudy, we were unable to reproduce the importance of change in hs-cTnT concentration over time in the prediction of outcome, despite similar cutoff levels for change (>15% relative change) and interval (3 months). Importantly, changes in hs-cTnT provided inferior prognostic information than that of elevated baseline levels in the present study. Nonetheless, from a clinical point of view, the prognostic value of baseline levels above or below the 99th percentile seems to be more important than that of changes during follow-up.
An explanation for these divergent findings might be differences in the composition of the study populations. Compared with the present CORONA substudy, the Val-HeFT and GISSI-HF study populations were younger (72±7 versus 63±11 [Val-HeFT] and 67±11 [GISSI-HF] years old), fewer were in NYHA class III and IV (67.9% versus 38.0% and 26.1%, respectively), had higher average eGFR (58.0 versus 61.7 and 61.9 mL/min per 1.73 m 2 , respectively), and the rate of HF with ischemic cause in these studies was ≈50%.
The mechanisms underlying hs-cTnT elevation in chronic HF remain unresolved. 26 A net effect of increased release of myocardial troponin into the circulation because of myocyte necrosis, apoptosis, or irreversible injury with increased myocyte membrane permeability and impaired renal clearance is a potential explanation. 27 The causes of cardiac myocyte necrosis, apoptosis, and increased membrane permeability might involve neurohormonal activation, oxidative stress, inflammatory cytokines, increased wall stress, altered calcium handling, and coronary artery disease. 27 This hypothesis is supported by the current study because in addition to eGFR, which is known to influence hs-cTnT levels, 28 diabetes mellitus (inflammation and oxidative stress), NT-proBNP levels (increased wall stress), hs-CRP levels (inflammation), increased heart rate and blood pressure (neurohormonal activation), and history of coronary revascularization (coronary artery disease) are associated with elevated hs-cTnT levels.
Limitations
The results of the present study are derived from a selected population of elderly patients with HF of ischemic origin included in the CORONA trial and may therefore not be applicable to a general HF population of mixed cause. In this respect, the frequency of comorbidities also warrants caution when interpreting the findings.
Conclusions
Elevated hs-cTnT levels in elderly patients with chronic HF of ischemic cause provide independent prognostic and discriminating information beyond that of established risk markers. The prognostic value of baseline hs-cTnT levels was superior to that of changes during follow-up. Forest plot demonstrating the predictive value (multivariate analysis) of change in high-sensitive troponin T (hs-cTnT) levels from baseline to 3 months on the primary end point, all-cause mortality, cardiovascular (CV) mortality, and the composite of CV mortality and hospitalization from worsening of heart failure (WHF). A significant change in hs-cTnT levels was defined as >15% relative change. Hazard ratios (HRs) are given as HR (95% confidence interval [CI]) with corresponding P value for the relative changes in hs-cTnT levels > or ≤15%. The multivariable regression model included the following risk factors: left ventricular ejection fraction, New York Heart Association class, age, body mass index, diabetes mellitus, sex, intermittent claudication, heart rate, apolipoprotein B/apolipoprotein A-1 ratio, amino-terminal probrain natriuretic peptide, high-sensitivity C-reactive protein, and estimated glomerular filtration rate.
